CClinicalTrials.gg
CompletedNCT02066103BROADWAYUpdated Apr 20, 2018

Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients

An interventional study of Paclitaxel in Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer, sponsored by Mercator MedSystems, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-20.

Sponsored by Mercator MedSystems, Inc. · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed.

This localized delivery is intended as an adjunct therapy and all subjects will receive standard of care oncology therapy as determined by their treating physicians.

02

Conditions studied

  • Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer

Browse trials for

03

In context

Airway Obstruction

154 studies on the registry are indexed under Airway Obstruction; 30 are open to participants now.

This study's enrollment of 20 is below the median of 56 across 92 interventional studies indexed under Airway Obstruction.

Browse Airway Obstruction studies →

Lead sponsor

Mercator MedSystems, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Life expectancy of at least 12 weeks
  • Adequate bone marrow, liver, and renal function
  • Scheduled to undergo bronchoscopy for malignant airway obstruction as standard medical care
  • Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer
  • Measurable disease with obstruction into the airway
  • Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer
  • Patients undergo recanalization procedure of tumor during bronchoscopy
  • Investigator is able to insert and deploy the Blowfish Catheter into the airway after recanalization

Exclusion criteria

Exclusion Criteria:

  • Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
  • Pregnant or nursing female subjects, or female subjects of child bearing potential who refuse to take a pregnancy test prior to their enrollment in this study
  • Uncontrolled infection
  • Presence or recent history of any systemic disorder or conditions, such as:

    • uncontrolled hypertension
    • type 1 diabetes
    • severe pulmonary hypertension
    • acute kidney injury
    • stroke (within the last 6 month)
    • myocardial infarction (within the last 3 months)
  • Individuals with neurological, mental or psychiatric disorders
  • Concurrent participation in another study involving investigational drugs or investigational medical devices
  • Other (non-cancer) disease not stabilized within 1 month before the Screening Visit
  • Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media
  • Any serious, uncontrolled comorbidity or condition that an Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient Intraoperative Exclusion Criteria
  • Use of pulmonary airway stents and/or ongoing or initiation of local external beam or brachytherapy radiation
  • Any intraoperative complications that per the investigator's judgment increase the risk to the patient.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment

    Drug: Paclitaxel

Interventions

  • DrugPaclitaxel
06

What researchers measure

Primary outcomes

  1. Treatment safety

    Adverse Events (AEs), Serious Adverse Events (SAEs), and all Unanticipated Adverse Device Effects (UADEs)

    Time frame: 12 weeks

  2. Technical success

    Device deployment and infusion success

    Time frame: procedure day

Secondary outcomes

  1. Airway patency improvements

    Time frame: 6 weeks

  2. Quality of Life

    Time frame: 12 weeks

07

Study locations

3 sites
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University
    Raleigh, North Carolina, United States
08

References and documents

Publications

  • Yarmus L, Mallow C, Akulian J, Lin CT, Ettinger D, Hales R, Voong KR, Lee H, Feller-Kopman D, Semaan R, Seward K, Wahidi MM. Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy. Chest. 2019 Sep;156(3):562-570. doi: 10.1016/j.chest.2019.02.006. Epub 2019 Feb 15. PubMed 30776363 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02066103
Lead sponsor
Mercator MedSystems, Inc.
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Jul 2014
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Apr 20, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion